Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT6 | P42226 | 7/20 | 0.50 |
| ▸ | AURKA | O14965 | 7/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 6/20 | 0.47 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.47 |
| ▸ | JAK3 | P52333 | 3/20 | 0.44 |
| ▸ | JAK2 | O60674 | 3/20 | 0.44 |
| ▸ | JAK1 | P23458 | 2/20 | 0.44 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.44 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.44 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.44 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2477145 | 0.84 | JAK3 (0.62) | STAT6AURKARPS6KB1AURKBJAK3 | |
| SCHEMBL2482050 | 0.80 | SYK (0.58) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL2512015 | 0.79 | STAT6 (0.56) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL12301660 | 0.76 | STAT6 (0.49) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL2481615 | 0.75 | STAT6 (0.58) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL2479743 | 0.73 | STAT6 (0.56) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL2485029 | 0.73 | STAT6 (0.60) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL2480538 | 0.73 | STAT6 (0.60) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL2477947 | 0.73 | STAT6 (0.74) | STAT6JAK3JAK2JAK1 | |
| SCHEMBL2510250 | 0.72 | STAT6 (0.54) | STAT6JAK3JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| US-8575153-B2 | Pyridine-3-carboxyamide derivative | KOWA COMPANY, LTD. (JP) | 2013-11-05 | — | — | US | disclosed |
| EP-2380877-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | Kowa Company, Ltd. (JP) | 2011-10-26 | — | — | EP | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | KOWA COMPANY, LTD. (JP) | 2011-09-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110237590-A1 | PYRIDINE-3-CARBOXYAMIDE DERIVATIVE | JAK3, JAK1, UACA | STAT6 8/4885AURKA 971/4885RPS6KB1 3316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.